Toray Files New Drug Application of TRK-820 Antipruritic Agent, Treatment of Severe Pruritus in Hemodialysis Patients in Japan.Tokyo, Japan, Nov 30, 2006 - (JCN) - Toray, JT and Torii Pharmaceutical announced November 28 that the companies have filed for a new drug application in Japan for TRK-820, an antipruritic antipruritic /an·ti·pru·rit·ic/ (-proo-rit´ik) preventing or relieving itching, or an agent that does this. an·ti·pru·rit·ic adj. Preventing or relieving itching. agent originally discovered by Toray. TRK-820 has been developed for treatment of severe uremic uremic pertaining to or emanating from uremia. uremic poisoning see uremia, visceral gout. uremic toxins pruritus pruritus /pru·ri·tus/ (proo-ri´tus) itching.prurit´ic pruritus a´ni intense chronic itching in the anal region. pruritus hiema´lis xerotic eczema. in hemodialysis patients based on the agreement signed by the three parties on March 16, 2005, for joint development and marketing. Hemodialysis-related uremic pruritus is a condition that causes systemic and severe itching, without inflammation, and with an unclear pathology. Hemodialysis patients with serious pruritus suffer from lack of sleep due to severe itching, which not only worsens their quality of life (QOL), but is also one of the causes of aggravated systemic symptoms. This itching cannot be fully suppressed by conventional antipruritic agents such as antihistamines Antihistamines Definition Antihistamines are drugs that block the action of histamine (a compound released in allergic inflammatory reactions) at the H1 , and development of effective drugs has long been awaited. TRK-820 is a selective kappa opioid receptor The κ-Opioid receptors are a class of opioid receptors with dynorphins as the primary endogenous ligands, and ketazocine as a potent selective exogenous ligand. There are three variants: κ1, κ2, and κ3. agonist and is expected to be effective with its novel mechanism in treating itching which is resistant to conventional drugs such as antihistamines. The application for the new drug has been filed by Toray, and subject to approval, the product will be marketed by Torii. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion